Phase 1/2 × Mycosis Fungoides × Lymphoid × Clear all
NCT06035497 2025-05-14

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Bristol-Myers Squibb

Phase 1/2 Recruiting
85 enrolled
NCT00002663 2023-02-13

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Atara Biotherapeutics

Phase 1/2 Completed
58 enrolled 18 charts
NCT00416351 2022-05-17

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
29 enrolled 15 charts
NCT01075321 2020-10-22

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
58 enrolled 12 charts
NCT00918333 2020-03-10

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Mayo Clinic

Phase 1/2 Completed
124 enrolled 10 charts
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT00474929 2019-08-20

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
103 enrolled 12 charts
NCT00290706 2019-05-28

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Northwestern University

Phase 1/2 Terminated
32 enrolled 12 charts
NCT00448357 2017-07-17

LCCC0510

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
54 enrolled 17 charts
NCT00601718 2017-05-25

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

University of Washington

Phase 1/2 Completed
29 enrolled 10 charts
NCT00112723 2016-08-08

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
46 enrolled 12 charts
NCT00823524 2013-02-20

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Asan Medical Center

Phase 1/2 Completed
47 enrolled
NCT00004907 2012-06-12

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Northwestern University

Phase 1/2 Completed
NCT00006225 2012-06-06

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Northwestern University

Phase 1/2 Completed
NCT00237627 2012-05-18

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
107 enrolled
NCT00089037 2011-07-15

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00010283 2010-04-02

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Fred Hutchinson Cancer Center

Phase 1/2 Completed